Product Description
a Topical Treatment for Actinic Keratosis (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01921907)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Assuta Hospital Systems
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Keratosis, Actinic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| AD17137 | P2 |
Completed |
Keratosis, Actinic |
2014-06-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|